Study of the Metabolism of Danicopan in Healthy Adults

Phase 1 Completed 24 enrolled Alexion Pharmaceuticals, Inc. Celerion · collab

RandomizedCrossoverOpen-labelBasic science

Summary

This is a 2-part open-label, randomized, single-dose, 3-sequence, 3-period crossover, relative bioavailability, and food-effect study comparing different formulations of danicopan in healthy adult participants.

Timeline

Start: 2020-10-20
Primary completion: 2020-12-07
Completion: 2020-12-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Danicopan	Small molecule	200 mg	Oral

Indications

No indication recorded.